Fill Finish Pharmaceutical Contract Manufacturing Market

Market Size

The fill finish pharmaceutical contract manufacturing market, valued at USD 7.2 billion in 2024, is project to reach USD 7.5 billion in 2025 and USD 12.1 billion by 2035, representing a CAGR of 4.8% during the forecast period 2025 to 2035.

Market Report: Key Takeaways

Market Size & Trends

• In terms of type of fill finish service offered, the terminal sterilization segment holds the highest share (~45%) of the market.
• With regards to type of FDF, the generic segment dominates the global market with more than 45% of the market share.
• Based on the API potency, the API segment holds the largest market share (close to 85%) in 2025.
• In terms of type of primary packaging container, the vials segment dominates the global market with 50% market share.
• With respect to scale of operation, commercial segment captures the highest share (close to 95%) in 2025.
• Based on the company size, the large and very large companies hold the majority of the market share.
• In terms of geographical regions, Europe captures the majority of the market share, and rest of the world is likely to grow at a faster pace in the near future.

Market Overview

Fill finish of small molecules is final step in the downstream processing of a product, wherein the desired formulation is mixed with the necessary excipients and stabilizers, followed by filling the purified bulk formulation into the pre-sterilized packaging containers (such as glass vials, prefilled syringes, cartridges and ampoules) and then finishing it by inspection, labeling and packaging. According to a recent study, small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. Further, the estimates suggest that in 2023, out of the 55 FDA approved drugs, 61% of the new drugs were small molecules. This percentage has been steadily rising, from 56% in 2021 (28 small molecule drugs out of 50 new drugs) to 57% in 2022 (21 small molecule drugs out of 37 new drugs).

Sterile fill finish of small molecules is considered to be one of the most crucial steps in the pharmaceutical production process. In fact, aseptic conditions during fill finish operations are not only essential for ensuring end user safety but are also essential for maintaining pharmacological efficacy and product quality. Notably, maintaining aseptic conditions during fill finish operations of novel small molecules-based formulations require specialized equipment and affiliated expertise, which further increases the production costs. Consequently, the increased capital expenditure poses significant challenges to the drug developers with limited finances and capacity constraints to meet the clinical and commercial demands; thereby, prompting the pharmaceutical companies to outsource their manufacturing operations to well-equipped contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs).

Driven by the need for specialized expertise and streamlined production workflows, growing pipeline and increasing complexity of small molecule drugs the demand for specialized fill finish manufacturing services in the pharmaceutical industry is on the rise. Further, given the increased focus on quality and multi-product strategies, the trend to incorporate advanced technologies, such as artificial intelligence and robotics has further increased the investment activity in this domain and are likely to drive the fill finish pharmaceutical contract manufacturing market growth in the near future.

Market Trends

• Focus on Hyper-Automation and Robotics: One of the key trend is hyper-automation and robotics. Technological innovations, such as aseptic isolators and restricted assess barrier systems (RABS) helps to separate the critical filling zone automatically. This will significantly reduce the chances of human-borne contamination. In addition, the focus will e on robotic filling lines to perform repetitive tasks, such as filling and capping, and container handling that leads to sterility assurance and higher precision.
• Adoption of Single-Use Technology: The growing emphasis on the single-use technology, such as single disposable filling needles, bag, and tubing will be the key trend. The single use technologies eliminate the need for complex cleaning and sterilization procedure. Moreover, it will also reduce the chances of cross-contamination.

Market Share Insights

Market Share by Type of Fill Finish Service Offered

• Currently, the terminal sterilization segment captures maximum share (44%) and is likely to dominate the market in the future as well.
• This can be primarily attributed to the fact that terminal sterilization provides the highest level of sterility assurance, is more reliable and cost-effective.

Market Share by Type of Primary Packaging Container

• The global market value is distributed into ampoules, cartridges, prefilled syringe, vials and other containers, based on the type of primary packaging container.
• The ampoules segment captures the highest fill finish pharmaceutical contract manufacturing share in current year and is expected to remain dominant during the forecast period.
• This can be primarily attributed to the various advantages offered by pharmaceutical vials, such as ease of filling, accurate and consistent dosing of the drug product and the ability to withstand sterilization processes like autoclaving. Further, it is worth highlighting that, in the coming years, prefilled syringes market segment is anticipated to grow at a relatively faster CAGR of 5.1%.

Market Share by Company Size

• Presently, the market is dominated by the revenues generated from large / very large service providers.
• This can be attributed to the fact that these companies have dedicated resources and deep expertise, sophisticated fill / finish facilities and robust regulatory capabilities.

Market Share by Geographical Regions

• According to our projections, Europe is likely to capture majority (38%) of the current fill finish pharmaceutical contract manufacturing market share.
• It is worth highlighting that the market in rest of the world is expected to grow at a relatively high CAGR (11%), during the period till 2035.

Market Insights

Advantages of Outsourcing Fill Finish Manufacturing Operations

Outsourcing fill finish manufacturing operations to CMOs allows the drug developers / pharmaceutical companies to focus on their core competencies, including research and development, marketing, and distribution. Further, outsourcing the manufacturing processes to specialized firms provides drug developers the access to well-established fill finish facilities and expertise, thereby enhancing efficiency and cost-effectiveness. Additionally, outsourcing can facilitate flexibility in scaling production capacity according to clinical and commercial demands.

Capacity Analysis: Fill Finish Manufacturing Capacity Installed in Facilities Owned by Large and Very Large Companies

Majority (48%) of the small molecules fill finish capacity for ampoules is installed at facilities located in Europe. Within Europe, close to 20% of the ampoule filling capacity is available with the facilities based in France. Moreover, for cartridges, close to 50% of the capacity is installed in Europe. Of these, more than 30% of the capacity is installed in the facilities located in France. Further, it is worth mentioning that, over the past few years, the vial filling capacity in Asia-Pacific has increased at a substantial pace. This growth can be attributed to the technological advancements, low labor costs and socio-economic reforms favoring the growth of specialty industries, such as the sterile fill finish industry in this region.

Market Segmentation Insights

Frequently Asked Questions